Zacks Research Comments on Humana’s Q3 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Analysts at Zacks Research raised their Q3 2025 earnings per share estimates for shares of Humana in a report issued on Wednesday, August 13th. Zacks Research analyst Team now expects that the insurance provider will post earnings of $2.51 per share for the quarter, up from their prior forecast of $1.68. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s Q4 2025 earnings at ($3.36) EPS, Q1 2026 earnings at $7.30 EPS, Q2 2026 earnings at $4.43 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at $12.94 EPS, Q1 2027 earnings at $9.21 EPS and FY2027 earnings at $20.86 EPS.

Other equities analysts have also recently issued research reports about the company. Barclays set a $275.00 price objective on Humana and gave the company an “equal weight” rating in a report on Thursday, July 31st. Raymond James Financial upgraded Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price objective for the company in a report on Thursday, May 1st. Morgan Stanley dropped their price objective on Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a report on Thursday, July 31st. Wells Fargo & Company decreased their target price on Humana from $348.00 to $344.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, Robert W. Baird decreased their target price on Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $281.43.

Humana Price Performance

Shares of Humana stock opened at $286.73 on Monday. The stock has a market cap of $34.49 billion, a price-to-earnings ratio of 22.01, a price-to-earnings-growth ratio of 1.68 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock has a 50 day moving average price of $242.70 and a 200-day moving average price of $253.24. Humana has a one year low of $206.87 and a one year high of $382.72.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analysts’ expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. Humana’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $6.96 EPS.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in HUM. Revolve Wealth Partners LLC purchased a new stake in Humana in the fourth quarter valued at about $202,000. Mariner LLC increased its holdings in shares of Humana by 4.0% during the fourth quarter. Mariner LLC now owns 13,461 shares of the insurance provider’s stock valued at $3,415,000 after acquiring an additional 517 shares in the last quarter. Forum Financial Management LP increased its holdings in shares of Humana by 62.0% during the fourth quarter. Forum Financial Management LP now owns 1,916 shares of the insurance provider’s stock valued at $486,000 after acquiring an additional 733 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of Humana by 78.6% during the fourth quarter. First Trust Advisors LP now owns 93,328 shares of the insurance provider’s stock valued at $23,678,000 after acquiring an additional 41,070 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Humana by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,059,737 shares of the insurance provider’s stock valued at $268,877,000 after acquiring an additional 19,091 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.